These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date and reported results 2008-007457-13 A Randomized, 6-Week, Double-Blind, Placebo-controlled, Fixed-Flexible-Dose, Parallel-Group Study of Lurasidone in the Treatment of Bipolar I Depression 2012-02-14 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-007482-23 A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel- Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression 2012-01-19 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-007483-42 A 24-Week, Flexible-Dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I Depression 2013-02-19 bad-data
Reported results 2010-018684-42 Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects with Partial Epilepsy Not Well Controlled by Current Antiepileptic Drug... 2012-11-27 due-trials
Reported results 2010-019000-22 Long-Term Eslicarbazepine Acetate Extension Study 2017-04-25 due-trials
Reported results 2010-019778-34 A RANDOMIZED, 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, FLEXIBLE-DOSE, PARALLEL-GROUP STUDY OF LURASIDONE ADJUNCTIVE TO LITHIUM OR DIVALPROEX FOR THE TREATMENT OF BIPOLAR I DEPRESSION IN SUBJECTS DEMO... 2012-08-07 due-trials
Reported results 2011-000682-12 A Long-term, Multicenter, Open-Label, Flexible Dose Continuation Study in Subjects Who Have Completed a Prior Lurasidone Study 2014-03-03 due-trials
Reported results 2011-000986-10 A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, FLEXIBLE-DOSE, PARALLEL-GROUP STUDY OF LURASIDONE ADJUNCTIVE TO LITHIUM OR DIVALPROEX FOR THE PREVENTION OF RECURRENCE IN SUBJECTS WITH BIPOLAR I DISORDE... 2015-04-04 due-trials
Reported results 2011-001711-31 A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance treatment of subjects with schizophrenia 2013-08-06 due-trials
Reported results 2011-004789-14 A Multicenter, Open-Label, Flexible-Dose Extension Study of Lurasidone Adjunctive to Lithium or Divalproex in Subjects with Bipolar I Disorder 2015-07-01 due-trials
Reported results 2011-004790-90 A 12-WEEK, MULTICENTER, OPEN-LABEL EXTENSION STUDY IN SUBJECTS WITH SCHIZOPHRENIA 2013-11-05 due-trials
Reported results Terminated 2012-004132-33 A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, 2014-04-03 due-trials
Reported results 2012-005271-14 A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LOW-DOSE LURASIDONE IN ACUTELY PSYCHOTIC SUBJECTS WITH SCHIZOPHRENIA 2014-06-18 due-trials
Trial is outside EEC, and reported results 2013-001523-39 A PHASE 1 OPEN-LABEL, MULTICENTER, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF LURASIDONE IN SUBJECTS 6 TO 17 YEARS OLD WITH SCHIZOPHRENIA SPECTR... bad-data
Trial is partly outside EEC, and reported results 2013-001694-24 A 104-Week, Flexible-Dose, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Effectiveness of Lurasidone in Pediatric Subjects 2018-10-17 bad-data
Trial is partly outside EEC, and reported results 2013-001695-38 A 6-Week Randomised, Parallel, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study To Evaluate The Efficacy and Safety of Lurasidone in Adolescent Subjects with Schizophrenia 2015-12-29 bad-data
Reported results 2013-002696-18 A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter, Long-Term Safety Trial of Treatment with Nebulized SUN-101 in Patients with COPD: GOLDEN-5 (Glycopyrrolate for Obstructive Lun... 2016-02-02 due-trials
Trial is partly outside EEC, and reported results 2013-004903-37 A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible Dose, Parallel-Group Study to Evaluate the Efficacy and Safety of Lurasidone in Children and Adolescent Subjects with Bipolar I Depress... 2016-10-12 bad-data
Completed, report not yet due 2016-000060-42 A 6-Week, Randomized, Double-Blind, Placebo-Controlled Study 2018-11-06 not-yet-due
Listed as ongoing, but also has a completion date 2016-000061-23 A 12-Week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with Schizophrenia 2019-01-31 bad-data
Not reported 2016-000636-18 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Co... 2017-12-11 due-trials
Ongoing 2016-000637-43 An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (“OFF” E... not-yet-due
Completed, report not yet due 2016-001555-41 A 4-Week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexibly-dosed, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adult Subjects With Sch... 2018-07-31 not-yet-due
Completed, report not yet due 2016-001556-21 A 26-Week Open-label Safety and Tolerability Extension Study of SEP-363856 in Adult Subjects with Schizophrenia 2019-01-29 not-yet-due
Ongoing, reported early 2016-001762-29 A Phase 2, Randomized, Double-Blind, Placebo Controlled, 3-Period Crossover, Positive Control, QT-Evaluation Study of APL-130277 in Subjects with Parkinson’s Disease Complicated by Motor Fluctuations ... not-yet-due
Ongoing 2016-003456-70 An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson's Disease Complicated by ... not-yet-due
Ongoing 2018-000103-16 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of SEP-4199 for the Treatment of Major Depressive Episode Associated with Bipolar I Disorder not-yet-due